Effect of serum high-sensitivity C-reactive protein and tumor necrosis factor-alpha on prognosis of patients undergoing percutaneous coronary intervention

Abstract

Objective To investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α) on the prognosis of patients undergoing percutaneous coronary intervention (PCI). Methods From January 2016 to December 2017, 197 patients with acute coronary syndrome (ACS) treated by PCI in our hospital were divided into MACE group (39 cases) and non-MACE group (158 cases) according to whether major adverse cardiovascular events (MACE) occurred after PCI.The serum levels of hs-CRP and TNF-α were compared between the two groups before and 48 hours after PCI.The risk factors of MACE after PCI were analyzed by logistic regression analysis. Results One year follow-up results after PCI showed that 39 of 197 ACS patients had MACE after PCI, with an incidence of 19.8% (39/197). There were 39 cases in MACE group and 158 cases in non-MACE group.The serum hs-CRP of the MACE group and the non-MACE group before PCI were (9.70±4.71), (7.50±4.61) mg/L respectively, and 48 hours after PCI were (15.37±5.01), (12.16±4.38) mg/L, respectively.There were significant differences between the two groups (all P<0.01). The serum TNF-α levels before PCI in MACE group and non-MACE group were (33.1±8.9), (25.7±8.0) ng/L, respectively, and 48 hours after PCI were (47.6±8.1), (32.4±7.6) ng/L, respectively.There were significant differences between the two groups (P<0.05 or P<0.01). The results of logistic regression analysis showed that preoperative serum hs CRP and TNF-α were the risk factors of mace in PCI patients (OR (95% CI) was 2.069 (1.715-3.358), 2.825 (1.614-4.372), P value was 0.020 and 0.027, respectively). Conclusion The serum levels of hs-CRP and TNF-α are related to the prognosis of patients with PCI.The serum levels of hs-CRP and TNF-α before PCI are risk factors for MACE, which can be used as independent predictors of MACE. Key words: Acute coronary syndrome; Percutaneous coronary intervention; Major adverse cardiovascular events; High-sensitivity C-reactive protein; Tumor necrosis factor-alpha